First Trials Set to Begin for BICX104, An Unprecedented Way for Patients to Receive Naltrexone

BICX104 is a biodegradable, implantable pellet that can be used for the treatment of various substance abuse disorders.

learn more about Emily Rella

By Emily Rella

There has undoubedtly been impressive progress made in the past decade in the world of addiction recovery services.

Yet the numbers of lives lost are still harrowing.

According to the CDC, there were 75,673 opioid-related overdose deaths from April 2020 to April 2021, a near 20,000 increase from the 12-month period prior.

An additional 49,000 deaths in 2020 were alcohol-induced, per the same data.

But the latest news from addiction treatment solutions company BioCorRx could change the way patients and treatment providers approach the process of recovery forever.

The company announced today that it has begun the process of recruiting and enlisting volunteers for the first-ever clinical trial of the highly-anticipated BICX104.

BICX104 is an unprecedented way for patients to get and take Naltrexone, a medication that is most popularly used for the treatment of addiction to alcohol and opioids, though its effects are used in treatment for a multitude of addictive disorders such as binge eating disorder.

Naltrexone has historically had two options for usage. It can be taken orally in a pill form but it typically is taken as a slow-release injectable, especially for the usage of treatment in opioid addiction. Naltrexone works by blocking the euphoric effects of alcohol, opioids, whatever it may be by binding to specific receptors (endorphin, opioid, etc.) in the body associated with the "high" that specific substances or behaviors correlate with.

But since taking the medication in both these routes are voluntary, patients who do not wish to take the medication will not benefit from the effects of it, making it a difficult way to manage recovery if the patient does not agree to or want to use the medicine in conjuction with other holistic methods, such as CBT sessions.

But with BICX104, patients in recovery won't have the option each day — the new medication will be an implantable pellet of Naltrexone that is biodegradable, the effects of which to be absorbed intramuscularly in each patient's body.

"This is an extremely important milestone as it marks the next phase of development for BICX104," Brady Granier, President, Director of BioCorRx Inc. and CEO of BioCorRx Pharmaceuticals Inc. said upon the beginning of trial recruitment. "This study will help evaluate the pharmacokinetics and safety of BICX104 compared to another marketed Naltrexone product. We believe that better compliance to Naltrexone therapy will ultimately lead to better patient outcomes. We strive to enroll all subjects as soon as possible and look forward to providing progress updates as they become available."

The study, which will be lead by Dr. Joel M. Neutel M.D., Director of Research at the Orange County Research Center Orange County Research Center (OCRC), is the first of its kind that will survey the safety and pharmacokinetics of the pellet in a group of random, healthy volunteers.

Patient 0 trials for BICX104 are set to begin next month.

Emily Rella

Entrepreneur Staff

News Writer

Emily Rella is a news writer at Entrepreneur.com. Previously, she was an editor at Verizon Media. Her coverage spans features, business, lifestyle, tech, entertainment, and lifestyle. She is a 2015 graduate of Boston College and a Ridgefield, CT native. Find her on Twitter at @EmilyKRella.

Related Topics

Editor's Pick

Everyone Wants to Get Close to Their Favorite Artist. Here's the Technology Making It a Reality — But Better.
The Highest-Paid, Highest-Profile People in Every Field Know This Communication Strategy
After Early Rejection From Publishers, This Author Self-Published Her Book and Sold More Than 500,000 Copies. Here's How She Did It.
Having Trouble Speaking Up in Meetings? Try This Strategy.
He Names Brands for Amazon, Meta and Forever 21, and Says This Is the Big Blank Space in the Naming Game
Thought Leaders

The Collapse of Credit Suisse: A Cautionary Tale of Resistance to Hybrid Work

This cautionary tale serves as a reminder for business leaders to adapt to the changing world of work and prioritize their workforce's needs and preferences.

Business News

'Could This Be True?': Blockbuster Might Be Teasing a Surprise Comeback

The company has shuttered all of its locations except for one in Bend, Oregon.

Business News

These Are the Most and Least Affordable Places to Retire in The U.S.

The Northeast and West Coast are the least affordable, while areas in the Mountain State region tend to be ideal for retirees on a budget.

Business News

I'm a Former Google Recruiter. Here's How to Land a Job in Tech — and What Can Blow Your Interview

A former Google recruiter says layoffs may be trendy, but tech workers are always needed. Here's how to land a job at a major tech company.

Growing a Business

The No.1 Most Bankable Skill You Must Have to Succeed in 2023

If you don't foster this skill, you'll fall behind the pack financially and professionally in 2023.